A Randomized Phase III Study to Compare Efficacy and Safety of BAT2206 (Proposed Ustekinumab Biosimilar) with Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis
{{output}}
Background: BAT2206 is a proposed biosimilar to reference ustekinumab (UST, Stelara®). Objectives: To compare the efficacy and safety of BAT22... ...
